Small fiber polyneuropathy: A new therapeutic target in patients with interstitial cystitis/bladder pain syndrome?
- PMID: 40778060
- PMCID: PMC12327272
- DOI: 10.3389/fruro.2023.1098294
Small fiber polyneuropathy: A new therapeutic target in patients with interstitial cystitis/bladder pain syndrome?
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disease that, based on the variable efficacy observed with most therapeutic options, is difficult to treat effectively. A more targeted patient selection process for current and emerging therapeutic options would likely help to improve outcomes. This narrative review explores small fiber polyneuropathy (SFPN) in IC/BPS as part of a larger widespread pain phenotype and as a potential therapeutic target. Because SFPN is becoming increasingly implicated in polysyndromic pain disorders (e.g., IC/BPS, chronic pelvic pain, and fibromyalgia) in which immune dysregulation is a suspected pathophysiologic etiology, continued consideration should be given to immunomodulatory therapies such as intravenous immunoglobulin (IVIg). Moreover, since the small fibers affected in SFPN continue to grow even as people age, targeted treatment may prevent further destruction and provide long-term benefits as the fibers are given time to repair. In addition to therapeutic potential, having a definitive SFPN diagnosis may provide psychological benefit in a patient population for which symptoms have historically been attributed to negative psychological factors. Finally, based on emerging data in this area, we propose consideration be given to include SFPN testing in the work-up of patients with IC/BPS that are refractory to treatments or have multiple comorbid pain syndromes since it may be an indicator of the need for alternative therapies. We believe that SFPN will play an increasingly larger role in the clinical evaluation and management of polysyndromic pain disorders, including IC/BPS.
Keywords: immunotherapy; interstitial cystitis/bladder pain syndrome; pain; small fiber polyneuropathy; therapeutics.
Copyright © 2023 Whitman, Sandberg, Lee and Walker.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jul 30;7(7):CD013325. doi: 10.1002/14651858.CD013325.pub2. Cochrane Database Syst Rev. 2020. PMID: 32734597 Free PMC article.
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. Health Technol Assess. 2024. PMID: 39367772 Free PMC article.
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
References
-
- Schachar JS, Evans RJ, Parks GE, Zambon J, Badlani G, Walker SJ. Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome. Int Urogynecol J (2019) 30(11):1863–70. doi: 10.1007/s00192-019-04038-0 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources